HMBOX1 Inhibitor for Muscle Atrophy Treatment

ChangeBridge: Patent Apps - Biotech (C12N)

Published March 26th, 2026

Detected March 27th, 2026

Summary

The USPTO has published a patent application (US20260085316A1) from Shanghai University detailing the use of a homeobox containing 1 (HMBOX1) inhibitor for the prevention and treatment of muscle atrophy. The application outlines findings from cellular and animal studies supporting the therapeutic potential of inhibiting HMBOX1 expression.

View original document View source feed page

What changed

This document is a published patent application from the USPTO, specifically application US20260085316A1, filed by Shanghai University. It describes a novel use of a homeobox containing 1 (HMBOX1) inhibitor in the preparation of a drug intended for the prevention and/or treatment of muscle atrophy. The application details experimental results at both cellular and animal levels that demonstrate the efficacy of inhibiting HMBOX1 expression in suppressing muscle atrophy.

As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on entities. However, it signifies a potential new therapeutic avenue for muscle atrophy, which may be of interest to pharmaceutical companies and researchers in the biotechnology and healthcare sectors. Companies involved in drug development for muscle-related conditions should monitor the progress of this patent application and related research.

Source document (simplified)

← USPTO Patent Applications

USE OF HOMEOBOX CONTAINING 1 (HMBOX1) INHIBITOR IN PREPARATION OF DRUG FOR PREVENTION AND/OR TREATMENT OF MUSCLE ATROPHY

Application US20260085316A1 Kind: A1 Mar 26, 2026

Assignee

Shanghai University

Inventors

Junjie XIAO, Jin LI, Tingting YANG, Yuying CHEN, Yuwei YAN

Abstract

Use of a homeobox containing 1 (HMBOX1) inhibitor in preparation of a drug for prevention and/or treatment of muscle atrophy. Functional experiments at the cellular level show that inhibiting the expression of HMBOX1 may effectively suppress the occurrence of muscle atrophy. Furthermore, functional experiments at the animal level demonstrate that inhibiting HMBOX1 expression has preventive and therapeutic effects against muscle atrophy. Therefore, the HMBOX1 inhibitor is used for the prevention and/or treatment of muscle atrophy, offering a new approach for the development of drugs that inhibit muscle atrophy.